Table 2.
Uni- and multivariable cause-specific Cox proportional hazards of the risk of CRPC.
| Univariable Analysis | Multivariable Analysis | |||
|---|---|---|---|---|
| HR (95% CI) | p Value | HR (95% CI) | p Value | |
| AZGP1 expression | ||||
| High | REF | REF | ||
| Low | 1.5 (1.0–2.1) | 0.03 | 1.3 (0.9–1.9) | 0.2 |
| Age at treatment start | 1.0 (1.0–1.02) | 0.5 | 1.0 (1.0–1.02) | 0.6 |
| PSA for 2-fold diff. | 1.2 (1.1–1.4) | <0.0001 | 1.2 (1.1–1.4) | <0.0001 |
| Clinical tumor category | ||||
| ≤cT2 | REF | REF | ||
| cT3a | 1.2 (1.0–8.4) | 0.5 | 0.9 (0.5–1.6) | 0.7 |
| cT3b | 2.0 (0.6–6.4) | 0.2 | 1.0 (0.5–1.7) | 0.9 |
| cT4 | 2.9 (0.9–9.6) | 0.07 | 1.1 (0.5–2.0) | 0.9 |
| Diagnostic Gleason score | ||||
| ≤7 | REF | REF | ||
| 8 | 1.4 (0.8–2.4) | 0.2 | 1.1 (0.6–1.8) | 0.9 |
| 9–10 | 1.8 (1.1–2.9) | 0.02 | 1.5 (0.9–2.5) | 0.1 |
| Stage of disease * | ||||
| Locally advanced | REF | REF | ||
| Lymph node metastases only | 0.8 (0.7–1.8) | 0.4 | 1.1 (0.6–2.0) | 0.8 |
| Distant metastases | 1.2 (0.5–1.4) | 0.5 | 1.0 (0.6–1.6) | 1.0 |
Abbreviations: CI: Confidence interval; CRPC: Castration-resistant prostate cancer; HR: Hazard ratio; PSA: Prostate-specific antigen. * Locally advanced: N0/Nx and M0/Mx; Lymph node metastases only: N1 and M0/Mx; Distant metastases: M1 and N0/Nx/N1.